A Phase 1b/2 open label dose escalation study of Margetuximab incombination with Pembrolizumab in patients with relapsed refrectory advanced HER2 + Gastroesophageal junction or gastric cancer.
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
MacroGenics, Inc.
Start Date
January 1, 2016
End Date
December 31, 2021
Administered By
Duke Cancer Institute
Awarded By
MacroGenics, Inc.
Start Date
January 1, 2016
End Date
December 31, 2021